Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01562548 · ClinicalTrials.gov registry record · NA
Exploratory Efficacy Study of Guaifenesin in Upper Back Pain
A NA study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- NA
- Development phase
- 78
- Enrollment target
NCT01562548 is a NA study that has completed, run by GlaxoSmithKline. The registered enrollment target is 78 participants.
The verdict
NCT01562548, a NA study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- NA
- Development phase
- 78 participants
- Enrollment target
Study Summary
Explore the clinical efficacy of 7-day treatment regimens of guaifenesin in order to investigate the evidence that guaifenesin is an effective treatment for upper back/neck/shoulder muscle spasm/stiffness and pain.
Interventions
- DRUG Placebo
- DRUG Guaifenesin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2012-02 |
| Est. Completion | 2013-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01562548
The ClinicalTrials.gov registry entry for NCT01562548 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01562548 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01562548 about?
NCT01562548 is a clinical study titled "Exploratory Efficacy Study of Guaifenesin in Upper Back Pain". Explore the clinical efficacy of 7-day treatment regimens of guaifenesin in order to investigate the evidence that guaifenesin is an effective treatment for upper back/neck/shoulder muscle spasm/stiffness and pain.
What is the current status of trial NCT01562548?
This trial is currently completed. It is a NA study. The enrollment target is 78 participants. The study started on 2012-02. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01562548?
The interventions under investigation include: Placebo (DRUG), Guaifenesin (DRUG).
Who is sponsoring clinical trial NCT01562548?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.